(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(-0.04%) $0.926
(-0.07%) $10.83
(-0.15%) $0.791
(-0.09%) $92.49
Live Chart Being Loaded With Signals
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project...
Stats | |
---|---|
Today's Volume | 277 900 |
Average Volume | 146 068 |
Market Cap | 65.17M |
EPS | SEK-0.0747 ( 2023-11-03 ) |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -0.720 |
ATR14 | SEK0.00400 (1.38%) |
Spago Nanomedical AB Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Spago Nanomedical AB Financials
Annual | 2023 |
Revenue: | SEK1.20M |
Gross Profit: | SEK-22.75M (-1 890.86 %) |
EPS: | SEK-0.430 |
Q4 | 2023 |
Revenue: | SEK731 000 |
Gross Profit: | SEK-5.01M (-684.95 %) |
EPS: | SEK-0.0792 |
Q3 | 2023 |
Revenue: | SEK271 000 |
Gross Profit: | SEK-2.22M (-820.30 %) |
EPS: | SEK-0.0747 |
Q2 | 2023 |
Revenue: | SEK114 000 |
Gross Profit: | SEK-2.68M (-2 350.88 %) |
EPS: | SEK-0.0900 |
Financial Reports:
No articles found.
Spago Nanomedical AB
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators